We previously found that the anti-cancer drug methylglyoxal bis(guanylhydrazone) (mitoguazone) depresses carnitine-dependent oxidation of long-chain fatty acids in cultured mouse leukaemia cells [Nikula, Alhonen-Hongisto, Seppanen & Janne (1984) Biochem. Biophys. Res. Commun. 120,[9][10][11][12][13][14]. We have now investigated whether carnitine also influences the development of the well-known mitochondrial damage produced by the drug in L1210 leukaemia cells. Palmitate oxidation was distinctly inhibited in tumour cells exposed to 5#M-methylglyoxal bis(guanylhydrazone) for only 7h. Electron-microscopic examination of the drug-exposed cells revealed that more than half of the mitochondria were severely damaged. Similar exposure of the leukaemia cells to the drug in the presence of carnitine not only abolished the inhibition of fatty acid oxidation but almost completely prevented the drug-induced mitochondrial damage. The protection provided by carnitine appeared to depend on the intracellular concentration of methylglyoxal bis(guanylhydrazone), since the mitochondria-sparing effect disappeared at higher drug concentrations.
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Although methylglyoxal bis(guanylhydrazone) (mitoguazone) is a potent inhibitor of eukaryotic Sadenosylmethionine decarboxylase (EC 4.1.1.50) (Williams-Ashman & Schenone, 1972) and hence retards the accumulation of spermidine and spermine, it is by no means proved that the prevention of polyamine accumulation is responsible for the profound antiproliferative action exerted by the compound. In addition to the effects directed towards the metabolism of the polyamines, methylglyoxal bis(guanylhydrazone) also affects the function and integrity of mitochondria. Pine & DiPaolo (1966) reported that the drug behaves as a mitochondrial poison, inhibiting cellular respiration and uncoupling oxidative phosphorylation. Pathak et al. (1977) (Janne et al., 1981) . The compound appears to inhibit selectively mitochondrial DNA synthesis ), yet a direct cause-and-effect (Byczkowski et al., 1981) . Methylglyoxal bis(guanylhydrazone) is likewise reported to compete with the natural polyamines for negatively charged binding sites at the mitochondrial membrane (Byczkowski & Porter, 1983) . Moreover, mitochondrial damage in the intestinal epithelium is suggested to be responsible for the antiproliferative toxicity of the drug (Pleshkewych et al., 1983) .
In addition to the above-cited effects on mitochondria, we found (Nikula et al., 1984) that methylglyoxal bis(guanylhydrazone) inhibited the mitochondrial oxidation of long-chain fatty acids. Interestingly, this inhibition was competitive in respect to carnitine (Nikula et al., 1984 
Analytical methods
The oxidation of palmitate, bound to defatted albumin (1:68, w/w), was determined in tumour cell suspension (in phosphate-buffered saline) as described by Nikula et al. (1984) . The reproducibility of the assay within the same experiment was very good (±10%), but varied between experiments, depending on the metabolic state of the cells. Intracellular contents of methylglyoxal bis-(guanylhydrazone) were determined by the enzyme-inhibition assay of Seppanen et al. (1980) .
Preparation of cells for electron microscopy
The cell pellets were fixed with 2.5% (v/v) glutaraldehyde in 0.1M-phosphate buffer (pH7.3) for 45min at room temperature. The cells were washed with the phosphate buffer and treated with a solution containing 1% OS04 for 90min. Dehydration of the fixed cell pellet was accomplished with graded ethanol treatments and the dehydrated pellet was finally mounted into epoxy resin and sliced for electron microscopy. The sliced sections were stained with lead citrate and uranyl acetate.
Results
As shown in Fig. 1 (parts a and b) were from the experiment presented in Table 1 . The mitochondria of tumour cells exposed to methylglyoxal bis(guanylhydrazone) were greatly swollen and had almost totally lost their normal structure ( Fig.  la) , whereas mitochondria in cells exposed to the drug in the presence of carnitine were apparently morphologically normal (Fig. lb) . In another experiment, the tumour cells were exposed to methylglyoxal bis(guanylhydrazone) in the absence or presence of carnitine for a slightly longer period. The intracellular drug concentrations now exceeded 1000 amol/cell (the uptake of Table 1 . Effect ofmethylglyoxal bis(guanylhydrazone) in the absence or presence ofDL-carnitine on the oxidation ofpalmitate and on mitochondrial morphology in LJ210 leukaemia cells
The cells were grown in the absence or presence of 5pM-methylglyoxal bis(guanylhydrazone) (MGBG) without or with 2mM-DL-carnitine for 7 h, after which palmitate oxidation waa measured and samples for electron microscopy were prepared. the drug is critically dependent on the growth rate of the cells; even a slight increase in the growth rate results in higher intracellular drug concentration). Practically all (96%) the mitochondria were severely damaged in cells exposed to the drug in the absence of carnitine. Distinct mitochondrial damage (present in 38% of the mitochondria) was also evident in cells exposed to methylglyoxal bis(guanylhydrazone) in the presence of carnitine, although the damage was not nearly as total as without carnitine. Fig. 1 (parts c and d) shows the ultrastructural changes in the same tumour cells described above: both the severity and the extent of the mitochondrial damage were more pronounced in cells exposed to methylglyoxal bis(guanylhydrazone) in the absence (Fig. Ic) than in the presence of carnitine (Fig. ld) .
After longer periods of exposure and at high intracellular drug concentrations, the protective effect of carnitine was totally lost and the inhibition of palmitate oxidation became irreversible.
Discussion
Methylglyoxal bis(guanylhydrazone) is a potent cytotoxic drug that is currently undergoing clinical re-evaluation for its use in the treatment of human cancer (Warrell & Burchenal, 1983; Janne et al., 1983) . Although the exact mode of action is still incompletely understood, it is believed that the cytotoxicity of methylglyoxal bis(guanylhydrazone) is related to its ability to inhibit polyamine biosynthesis (Williams-Ashman & Schenone, 1972) and to the fact that the drug behaves as a mitochondrial poison (Pathak et al., 1977) . Although the morphological features of methyl-P.-Nikula, H. Ruohola, L. Alhonen-Hongisto and J. Janne glyoxal bis(guanylhydrazone)-induced mitochondrial damage are well documented, practically nothing is known about the biochemical basis of the selective (Pathak et al., 1977) destruction of mitochondria, but not of other cell organelles.
The fact that methylglyoxal bis(guanylhydrazone) inhibits the oxidation of long-chain fatty acids (Nikula et al., 1984) As there appears to be a certain threshold concentration at which the protection by carnitine disappears, the protective effect may be directed to tissues in which the accumulation of the drug is slow, such as parenchymal organs and muscle tissues (Kallio et al., 1983) . Especially interesting is the view that the frequently reported muscle symptoms during the treatment of human patients with methylglyoxal bis(guanylhydrazone) (Warrell & Burchenal, 1983; Janne et al., 1983) are based on an impaired fatty acid oxidation and could thus be alleviated with the administration of carnitine, which, in fact, is registered in many countries for human use.
